MetaCap

Enlivex (ENLV) vs Eocene (EOCN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enlivex is the larger company by market cap ($2.0 million vs $1.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENLV+242.69%EOCN-48.52%
+823%+366%-91%
Oct 7, 20261 yearNov 20, 2026
ENLV+313.39%EOCN-49.71%
+633%+276%-82%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENLV versus EOCN key metrics
MetricENLVEOCN
Share price$1.05$1.78
Market cap$2.01M$1.90M
1-day change-11.76%+1.73%
P/E ratio (TTM)0.00—
EPS (TTM)$7,904.00$-15.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.24B$-10.31M
52-week high$434.40$10.08
52-week low$1.00$1.75
Distance from 52-week high-99.76%-82.34%
Analyst consensusnonenone
Avg. price target upside+7519.05%—
Average volume73.14K18.17K
Shares outstanding1.91M1.07M
Employees343
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About Eocene

EOCN stock →

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

ENLV vs EOCN FAQ

Which is bigger, Enlivex or Eocene?

Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.90M for Eocene (EOCN).

Are Enlivex and Eocene in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons